NASDAQ:HROW
Harrow Inc. (HROW)
Financials 
Technical Analysis 
Sep 1, 2026, 12:00 amThis summary was created by AI, based on 5 opinions in the last 12 months.
Harrow Inc. (HROW-Q) is a volatile stock currently navigating challenges but has potential for growth, especially with its recent drug launch, despite initial slower progress than anticipated due to strong competition. The company's earnings missed expectations with $0.22 versus $0.26, and revenue fell short at $71.6 million against a predicted $73.7 million, primarily due to disruptions in certain business areas. Nonetheless, there is optimism surrounding their branded products, which are gaining traction and volumes, indicating a robust demand. The completion of the MELT acquisition is expected to provide a tailwind for future growth, while their focus on eye care biotechnology, particularly in addressing dry eyes and anesthetics for surgeries, positions them favorably for significant revenue growth and improved margins over the next few years. Analysts are generally favorable towards the stock, with a consensus buy rating and a target price suggesting substantial upside.
HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here.
Unlock Premium - Try 5i Free
HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here.
Unlock Premium - Try 5i Free
HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here.
Unlock Premium - Try 5i Free
It is in the eye care business and focuses on ophthalmology and biotech. One question is how easily can they get drugs to patients. Their first interesting drug is for dry eyes and the second is an anesthetic for surgeries, especially cataract surgery. This one is stable and consistent from patient to patient. Other anesthetics vary in their length of time they are effective from patient to patient. Has stable cash flows from its compounding business and accelerating growth from key products. Could get from under $300 million in revenue today to $1 billion in revenue in the next four years as well as tripling margins. Buy 8 Hold 0 Sell 0
(Analysts’ price target is $59.83)
Julien Nono-Womdim- «
- ‹
- 1
- ›
- »
Popular Articles
Harrow Inc. (HROW) Frequently Asked Questions
What is Harrow Inc. stock symbol?
Harrow Inc. is a American stock, trading under the symbol HROW (previously HROW-Q on Stockchase) on the NASDAQ (HROW). It is usually referred to as NASDAQ:HROW or HROW
Is Harrow Inc. a buy or a sell?
In the last year, 5 stock analysts issued a Buy, Sell, or Hold rating on HROW (previously HROW-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Harrow Inc..
Is Harrow Inc. a good investment or a top pick?
Harrow Inc. was recommended as a Top Pick by Julien Nono-Womdim on 2026-02-10. Read the latest stock experts ratings for Harrow Inc..
Why is Harrow Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Harrow Inc..
Is Harrow Inc. worth watching?
Harrow Inc. is covered by Stockchase experts and is worth watching.
What is Harrow Inc. stock price?
On 2026-09-01, Harrow Inc. (HROW) stock closed at a price of $36.97.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999944)'%3e%3cg%20id='Group-8'%20transform='translate(90.000000,%200.000000)'%3e%3cpath%20d='M11.4997292,5.58581788e-05%20C12.2854126,-0.00429698998%2013.2541635,0.496661868%2013.6456551,1.25176162%20L13.7121092,1.39625969%20L15.7478626,6.4533458%20L21.0287785,6.8043135%20C21.60867,6.84285288%2022.1472423,7.12366313%2022.5172746,7.58041175%20C23.2234049,8.45202216%2023.142035,9.7221751%2022.3571045,10.4940309%20L22.2340987,10.60596%20L18.0726557,14.1089676%20L19.3563392,19.5925566%20C19.4721567,20.0873014%2019.3941255,20.6085828%2019.1388305,21.0456062%20C18.6243292,21.9263484%2017.5369557,22.2447761%2016.6497127,21.8011012%20L16.5113976,21.7246849%20L11.5,18.7716134%20L6.48860242,21.7246849%20C5.5790916,22.2767372%204.40274983,21.9727033%203.86116953,21.0456062%20C3.60587449,20.6085828%203.52784326,20.0873014%203.64366079,19.5925566%20L4.9273443,14.1089676%20L0.76590125,10.60596%20C-0.13192926,9.85018675%20-0.258711404,8.49560268%200.482725407,7.58041175%20C0.85275775,7.12366313%201.39132997,6.84285288%201.97122149,6.8043135%20L7.25213737,6.4533458%20L9.28789079,1.39625969%20C9.62402537,0.561256055%2010.6655161,-0.00457632221%2011.4997292,5.58581788e-05%20Z'%20id='top-picks-.-icon-copy-7'%20fill='%23FFB800'%3e%3c/path%3e%3cpath%20d='M11.4997292,2.77818228e-05%20C12.2854126,-0.00429698998%2013.2541635,0.496661868%2013.6456551,1.25176162%20L13.7121092,1.39625969%20L15.7478626,6.4533458%20L21.0287785,6.8043135%20C21.60867,6.84285288%2022.1472423,7.12366313%2022.5172746,7.58041175%20C23.2234049,8.45202216%2023.142035,9.7221751%2022.3571045,10.4940309%20L22.2340987,10.60596%20L18.0726557,14.1089676%20L19.3563392,19.5925566%20C19.4721567,20.0873014%2019.3941255,20.6085828%2019.1388305,21.0456062%20C18.6243292,21.9263484%2017.5369557,22.2447761%2016.6497127,21.8011012%20L16.5113976,21.7246849%20L11.5,18.7716134%20C11.4998195,6.25722299%2011.4997292,2.77818228e-05%2011.4997292,2.77818228e-05%20Z'%20id='top-picks-.-icon-copy-8'%20fill='%23EAEAEA'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
'%20fill='%23EAEAEA'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M131.499729,2.82302245e-05%20C132.285413,-0.00432461793%20133.254164,0.496634241%20133.645655,1.25173399%20L133.712109,1.39623206%20L135.747863,6.45331817%20L141.028779,6.80428588%20C141.60867,6.84282525%20142.147242,7.1236355%20142.517275,7.58038413%20C143.223405,8.45199453%20143.142035,9.72214747%20142.357105,10.4940033%20L142.234099,10.6059323%20L138.072656,14.10894%20L139.356339,19.592529%20C139.472157,20.0872738%20139.394126,20.6085551%20139.13883,21.0455786%20C138.624329,21.9263208%20137.536956,22.2447485%20136.649713,21.8010736%20L136.511398,21.7246573%20L131.5,18.7715858%20L126.488602,21.7246573%20C125.579092,22.2767096%20124.40275,21.9726757%20123.86117,21.0455786%20C123.605874,20.6085551%20123.527843,20.0872738%20123.643661,19.592529%20L124.927344,14.10894%20L120.765901,10.6059323%20C119.868071,9.85015912%20119.741289,8.49557505%20120.482725,7.58038413%20C120.852758,7.1236355%20121.39133,6.84282525%20121.971221,6.80428588%20L127.252137,6.45331817%20L129.287891,1.39623206%20C129.624025,0.561228427%20130.665516,-0.00460395016%20131.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-8'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
A volatile stock. A recent drug launch has been good, though a little slower than expected. There's a lot of competition, but he expects growth. They so well buying companies and striking relationships with doctors.